title: [S-1 treatment for elderly patients over 75 years with gastric cancer].
abstract: BACKGROUND
  In our hospital, the starting dose of S-1 for patients over 75 years of age with advanced gastric cancer was determined by body surface of area, creatinine clearance, performance status(PS)and the presence of complications. The objective of this retrospective study was to investigate the proper administration of S-1 in elderly patients by comparing patients given a standard dose of S-1 to those given a reduced dose.
  
  
  METHODS
  Twenty patients participated. Six patients were administered S-1 at a standard dose(standard group)and fourteen patients with at a reduced dose(reduced group). Safety, feasibility and anti-tumor effects were assessed.
  
  
  RESULTS
  Three cases of grade 3 adverse events were found in the standard group, and one case was found in the reduced group. Time to treatment failure was 4. 4 months for the standard group and 8. 2 months for the reduced group. The overall response rate was 25% in the standard group and 30% in the reduced group.
  
  
  CONCLUSIONS
  It is important to reduce S-1 administration to patients over 75 years of age with caution, and take into account the patient's renal function, PS and Ccr complications.
authors.affiliation: Dept. of Surgery, NTT West Osaka Hospital, Japan.
authors.forename: Susumu
authors.initials: S
authors.lastname: Miyazaki
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kimura
authors.forename: Katsuki
authors.initials: K
authors.lastname: Danno
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Kanou
authors.forename: Tadashi
authors.initials: T
authors.lastname: Onishi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Tono
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Nakano
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yano
authors.forename: Takushi
authors.initials: T
authors.lastname: Monden
authors.forename: Shingi
authors.initials: S
authors.lastname: Imaoka
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D010094:Oxonic Acid / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy*; D005641:Tegafur / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid